In 166 patients with resected early-stage ALK-positive NSCLC, adjuvant crizotinib for up to 2 years did not improve disease-free survival vs observation or placebo (median 74·6 vs 75·1 months; HR 1·08, 95% CI 0·61–1·90). Grade ≥3 events on crizotinib: 58%.
RCTn = 166
Gerber et al. Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial